17234594|t|Abeta40 inhibits amyloid deposition in vivo.
17234594|a|Numerous studies have established a pivotal role for Abeta42 in Alzheimer's disease (AD) pathogenesis. In contrast, although Abeta40 is the predominant form of amyloid beta (Abeta) produced and accumulates to a variable degree in the human AD brain, its role in AD pathogenesis has not been established. It has generally been assumed that an increase in Abeta40 would accelerate amyloid plaque formation in vivo. We have crossed BRI-Abeta40 mice that selectively express high levels of Abeta40 with both Tg2576 (APPswe, K670N+M671L) mice and BRI-Abeta42A mice expressing Abeta42 selectively and analyzed parenchymal and cerebrovascular Abeta deposition in the bitransgenic mice compared with their singly transgenic littermates. In the bitransgenic mice, the increased steady-state levels of Abeta40 decreased Abeta deposition by 60-90%. These results demonstrate that Abeta42 and Abeta40 have opposing effects on amyloid deposition: Abeta42 promotes amyloid deposition but Abeta40 inhibits it. In addition, increasing Abeta40 levels protected BRI-Abeta40/Tg2576 mice from the premature-death phenotype observed in Tg2576 mice. The protective properties of Abeta40 with respect to amyloid deposition suggest that strategies that preferentially target Abeta40 may actually worsen the disease course and that selective increases in Abeta40 levels may actually reduce the risk for development of AD.
17234594	17	35	amyloid deposition	Disease	MESH:D058225
17234594	98	105	Abeta42	Gene	351
17234594	109	128	Alzheimer's disease	Disease	MESH:D000544
17234594	130	132	AD	Disease	MESH:D000544
17234594	205	217	amyloid beta	Gene	351
17234594	219	224	Abeta	Gene	351
17234594	279	284	human	Species	9606
17234594	285	287	AD	Disease	MESH:D000544
17234594	307	309	AD	Disease	MESH:D000544
17234594	424	438	amyloid plaque	Disease	MESH:D058225
17234594	474	477	BRI	CellLine	CVCL:2318
17234594	486	490	mice	Species	10090
17234594	549	555	Tg2576	CellLine	CVCL:S723
17234594	565	570	K670N	ProteinMutation	tmVar:p|SUB|K|670|N;HGVS:p.K670N;VariantGroup:1;OriginalGene:11820;CorrespondingGene:351;RS#:371425292;CorrespondingSpecies:10090;CA#:319103474
17234594	571	576	M671L	ProteinMutation	tmVar:p|SUB|M|671|L;HGVS:p.M671L;VariantGroup:0;OriginalGene:11820;CorrespondingGene:351;RS#:572842823;CorrespondingSpecies:10090;CA#:319103456
17234594	578	582	mice	Species	10090
17234594	587	590	BRI	CellLine	CVCL:2318
17234594	600	604	mice	Species	10090
17234594	616	623	Abeta42	Gene	351
17234594	681	686	Abeta	Gene	11820
17234594	718	722	mice	Species	10090
17234594	794	798	mice	Species	10090
17234594	855	860	Abeta	Gene	11820
17234594	914	921	Abeta42	Gene	351
17234594	959	977	amyloid deposition	Disease	MESH:D058225
17234594	979	986	Abeta42	Gene	351
17234594	996	1014	amyloid deposition	Disease	MESH:D058225
17234594	1089	1092	BRI	CellLine	CVCL:2318
17234594	1101	1107	Tg2576	CellLine	CVCL:S723
17234594	1108	1112	mice	Species	10090
17234594	1122	1137	premature-death	Disease	MESH:D003643
17234594	1160	1166	Tg2576	CellLine	CVCL:S723
17234594	1167	1171	mice	Species	10090
17234594	1226	1244	amyloid deposition	Disease	MESH:D058225
17234594	1438	1440	AD	Disease	MESH:D000544
17234594	Positive_Correlation	MESH:D058225	351
17234594	Association	MESH:D000544	351

